The rise of AI has been accompanied by an explosion of processing horsepower.
News, analysis and comment from the Financial Times, the worldʼs leading global business publication.
Early in the testing phase of Apple’s M1 chipset, a milestone new product for the company, the processor was installed in a batch of Mac computers and given to staffers working on applications that demanded heavy processing power. It was a pivotal moment: the first time Apple had made its own chip for any of its computers, shifting away from years of using a one-size-fits-all option from Intel.
After multiple teams tested the devices for a few hours while working on tasks, they reported lightning-fast performance but nearly all flagged an apparent problem. The MacBook Pro’s battery indicator, featured on the upper right hand corner of the computers, was broken. It had barely moved despite running power-hungry programs, the company told CNN Business.
The gag, of course, is that the battery indicator was working just fine. The M1 chip was so efficient, according to Apple, that it showed no real strain — one of several major selling points for products that now carry the chip. (Apple promises 20 hours of battery life for its 13-inch M1 MacBook Pro — what it says is the longest battery in any Mac to date).
There’s some really interesting CRISPR news out today, and it’s likely to be a forerunner of much more news to come. A research team has demonstrated what looks like robust, long-lasting effects in a primate model after one injection of the CRISPR enzymatic machinery. There have been plenty of rodent reports on various forms of CRISPR, and there are some human trials underway, but these is the first primate numbers that I’m aware of.
The gene they chose to inactivate is PCSK9, which has been a hot topic in drug discovery for some years now. It’s a target validated by several converging lines of evidence from the human population (see the “History” section of that first link). People with overactive PCSK9 have high LDL lipoproteins and cholesterol, and people with mutations that make it inactive have extremely low LDL and seem to be protected from a lot of cardiovascular disease. There are several drugs and drug candidates out there targeting the protein, as well there might be.
It’s a good proof-of-concept, then, because we know exactly what the effects of turning down the expression of active PCSK9 should look like. It’s also got the major advantage of being mostly a liver target – as I’ve mentioned several times on the blog already, many therapies aimed at gene editing or RNA manipulation have a pharmacokinetic complication. The formulations used to get such agents intact into the body (and in a form that they can penetrate cells) tend to get combed out pretty thoroughly by the liver – which after all, is (among other things) in the business of policing the bloodstream for weird, unrecognized stuff that is then targeted for demolition by hepatocytes. Your entire bloodstream goes sluicing through the liver constantly; you’re not going to able to dodge it if your therapy is out there in the circulation. It happens to our small-molecule drugs all the time: hepatic “first pass” metabolism is almost always a factor to reckon with.
French businesses are betting on insects as food. We explore the off-limit foods that might soon be on our plates.
Check out VICE News for more: http://vicenews.com.
Continue reading “Inside One of the World’s Largest Edible Insect Factories” »
The need for more web watchmen spans from private businesses to government agencies, experts say, and most of the job openings are in California, Florida, Texas and Virginia. That means for anyone looking to switch careers and considering a job in cybersecurity, there’s no greater time than now to find work, the job trackers said.
“You don’t have to be a graduate of MIT to work in cybersecurity,” said Tim Herbert, executive vice president for research at CompTIA. “It just requires someone who has the proper training, proper certification and is certainly committed to the work.”
Pediatrician, Medical Innovator, Educator — Dr. Jamie Wells, MD, FAAP — Director, Research Science Institute (RSI), Center for Excellence in Education, Massachusetts Institute of Technology (MIT) — Professor, Drexel University School of Biomedical Engineering, Science and Health Systems.
Dr. Jamie L. Wells, MD, FAAP, is an Adjunct Professor at Drexel University’s School of Biomedical Engineering, Science and Health Systems, where she has been involved in helping to spearhead the nation’s first-degree program focused on pediatric engineering, innovation, and medical advancement.
Companies caught in the middle of the global semiconductor shortage, which is roiling the car business, are starting to see light at the end of the tunnel.
There’s a wide world of delivery logistics going on behind the scenes in America, one that’s become central to everyday life. And yet, most of us are completely oblivious to its environmental cost. But thanks to a handful of ambitious startups, there’s an electric revolution happening that may be perfectly suited to delivering us a cleaner future.
#Accelerate #EV #BloombergQuicktake.
——-
Like this video? Subscribe: https://www.youtube.com/Bloomberg?sub_confirmation=1
Become a Quicktake Member for exclusive perks: https://www.youtube.com/bloomberg/join.
Continue reading “The Way We Get Everything Is Going Electric” »
Eight months on, the semiconductor shortage seems likely to stretch into 2022. Increasing chip production is a slow and difficult business.
Cryptocurrencies like Bitcoin have been billed as a major disruptor to finance. But digital currencies issued by governments might be even more radical—they may even threaten the future of traditional banking.
Read our special report, “The Future of Banking” : https://econ.st/3tuTT8y.
Continue reading “Could digital currencies put banks out of business? | The Economist” »
